C4 THERAPEUTICS INC (CCCC) Stock Price, Quote, News and Overview
NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD
CCCC Quote, Performance and Key Statistics
3.01
+0.02 (+0.67%)
The current stock price of CCCC is 3.01 USD. In the past month the price decreased by -19.52%. In the past year, price decreased by -66.52%.
CCCC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CCCC
Company Profile
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 145 full-time employees. The company went IPO on 2020-10-02. The company is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919.
Company Info
C4 THERAPEUTICS INC
490 Arsenal Way, Suite 120
Watertown MASSACHUSETTS 02472 US
CEO: Andrew J. Hirsch
Employees: 145
Company Website: https://c4therapeutics.com/
Investor Relations: https://ir.c4therapeutics.com/
Phone: 16172310700
C4 THERAPEUTICS INC / CCCC FAQ
What is the stock price of C4 THERAPEUTICS INC today?
The current stock price of CCCC is 3.01 USD. The price increased by 0.67% in the last trading session.
What is the ticker symbol for C4 THERAPEUTICS INC stock?
The exchange symbol of C4 THERAPEUTICS INC is CCCC and it is listed on the Nasdaq exchange.
On which exchange is CCCC stock listed?
CCCC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for C4 THERAPEUTICS INC stock?
15 analysts have analysed CCCC and the average price target is 16.32 USD. This implies a price increase of 442.19% is expected in the next year compared to the current price of 3.01. Check the C4 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is C4 THERAPEUTICS INC worth?
C4 THERAPEUTICS INC (CCCC) has a market capitalization of 212.48M USD. This makes CCCC a Micro Cap stock.
How many employees does C4 THERAPEUTICS INC have?
C4 THERAPEUTICS INC (CCCC) currently has 145 employees.
Is C4 THERAPEUTICS INC (CCCC) expected to grow?
The Revenue of C4 THERAPEUTICS INC (CCCC) is expected to grow by 66.27% in the next year. Check the estimates tab for more information on the CCCC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy C4 THERAPEUTICS INC (CCCC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CCCC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CCCC, evaluating the profitability, health, valuation and growth aspects
- C4 THERAPEUTICS INC (CCCC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- C4 THERAPEUTICS INC (CCCC) Sales and EPS estimates to see what analysts future expectations are.
- C4 THERAPEUTICS INC (CCCC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- C4 THERAPEUTICS INC (CCCC) Insider and Institutional Ownership to learn about the owners and their transactions.
- C4 THERAPEUTICS INC (CCCC) Stock Chart to make your own analysis
- C4 THERAPEUTICS INC (CCCC) Latest news and press-releases to stay up to date.
Does C4 THERAPEUTICS INC (CCCC) stock pay dividends?
CCCC does not pay a dividend.
When does C4 THERAPEUTICS INC (CCCC) report earnings?
C4 THERAPEUTICS INC (CCCC) will report earnings on 2025-05-06.
What is the Price/Earnings (PE) ratio of C4 THERAPEUTICS INC (CCCC)?
C4 THERAPEUTICS INC (CCCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
What is the Short Interest ratio of C4 THERAPEUTICS INC (CCCC) stock?
The outstanding short interest for C4 THERAPEUTICS INC (CCCC) is 12.75% of its float. Check the ownership tab for more information on the CCCC short interest.
CCCC Technical Analysis
CCCC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CCCC. No worries on liquidiy or solvency for CCCC as it has an excellent financial health rating, but there are worries on the profitability.
CCCC Financial Highlights
Over the last trailing twelve months CCCC reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS increased by 37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.05% | ||
| ROE | -43.48% | ||
| Debt/Equity | 0 |
CCCC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CCCC. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 40.95% and a revenue growth 66.27% for CCCC